EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

Relationship between lipoprotein(a), fibrinogen, and fibronectin in non‐diabetic hemodialyzed uremic patients

Helen A. Tzanatos, Kalliopi Retsa, Lygeri Soubassi, Dimitris Rizos, Marios Skiadas, George Bougatsos, Basil Agroyannis

Dialysis & Transplantation · 2006

DOI: 10.1002/dat.20005 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract Background Lipoprotein(a), Lp(a), has been recognized as an atherogenic and thrombogenic lipoprotein in the general population and in hemodialysis (HD) patients. In addition, fibrinogen and fibronectin may promote atherothrombosis. The aim of this study was to investigate any possible relationship between Lp(a) and thrombogenic coagulation proteins in non‐diabetic HD patients. Patients and Methods Serum Lp(a) and plasma fibrinogen, plasminogen, and fibronectin levels were measured pre‐HD in 60 uremic patients (30 male, 30 female) aged 58.6±8.0 years who had been receiving HD treatment for 61.3±50.7 months. The control group comprised 20 age‐ and sex‐matched healthy subjects. All patients were receiving erythropoietin treatment. Results The mean serum Lp(a) (33.88±34.12 mg/dL) and plasma fibrinogen (329.45±80.62 mg/dL) levels were significantly higher in the HD patients compared with those in the controls (16.70±10.36 and 254.00±43.34 mg/dL, respectively; p

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →